Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18056091 | 0.84 | ITGB3 (0.43) | ITGB3ITGA2B | |
| SCHEMBL24860034 | 0.83 | NAAA (0.40) | NAAASMN1; SMN2KEAP1NFE2L2EPHX1 | |
| SCHEMBL23085465 | 0.78 | NAAA (0.38) | NAAASMN1; SMN2EPHX1 | |
| SCHEMBL22986172 | 0.74 | EPHX1 (0.40) | NAAASMN1; SMN2EPHX1 | |
| SCHEMBL22054572 | 0.74 | SMN1; SMN2 (0.45) | SIGMAR1SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL25573548 | 0.74 | SMN1; SMN2 (0.45) | SIGMAR1SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL14525109 | 0.72 | KISS1R (0.47) | SMN1; SMN2EPHX1 | |
| SCHEMBL13057114 | 0.72 | CPB2 (0.43) | SMN1; SMN2EPHX1 | |
| SCHEMBL19401625 | 0.72 | CPB2 (0.43) | SMN1; SMN2EPHX1 | |
| SCHEMBL9976417 | 0.72 | KISS1R (0.47) | SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220001022-A1 | Immunoconjugates Targeting HER2 | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220001022-A1 | Immunoconjugates Targeting HER2 | ERBB2, EGFR, FCGR2A | SIGMAR1 1616/4885NAAA 3766/4885SMN1; SMN2 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.